Brian F. Kiesel

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

Frank P. Vendetti, Pooja Karukonda, David A. Clump et al. · Journal of Clinical Investigation · 2018 · 209 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Jiuping Ji, Robert J. Morgan et al. · Clinical Cancer Research · 2012 · 201 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <i>BRCA</i> Mutation–Associated Breast Cancer

Eve T. Rodler, Brenda F. Kurland, Melissa Griffin et al. · Clinical Cancer Research · 2016 · 97 citations · Full text

Medicine, Oncology, Pharmacology +13

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Jame Abraham, A.J. Montero, Rachel C. Jankowitz et al. · Journal of Clinical Oncology · 2019 · 80 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).

Shannon Puhalla, Jan H. Beumer, Shalu Pahuja et al. · Journal of Clinical Oncology · 2014 · 62 citations

Medicine, Oncology, Pharmacology +17